Porton Advanced and NovaCell Therapeutics Announced Strategic Cooperation to Accelerate NK Cell Therapy Development

September 2, 2025, Suzhou — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership to accelerate NK cell therapy development with NovaCell Therapeutics, an innovator in cancer therapeutics and cell regenerative medicine.

Porton Advanced has developed two platforms for NK cell production: one that relies on feeder cells and another that is free of feeder cells. The company provided CMC, registration, and declaration support services for China’s first allogeneic peripheral blood NK cell drug without genetic modification to obtain FDA clinical trial approval. Currently, Porton Advanced is executing multiple CAR-NK and NK IND-enabling CMC projects. Under the agreement, Porton Advanced will provide process development, GMP manufacturing, and support for drug registration and declaration to facilitate NovaCell Therapeutics’ NK cell therapy to get IND approval.

Wang Jianzhong, chairman of NovaCell Therapeutics, stated: “The successful screening of super NK cells represents a decade of our team's R&D efforts. We have addressed key challenges related to the limited survival rate of NK cells in the human body, their limited efficacy against solid tumors, and the achievement of both treatment and prevention simultaneously. We aim to complete clinical trials in three years and achieve large-scale production in five years, with Porton Advanced's CDMO support. ”
Andrew Chen, CEO of Porton Advanced, stated: “NovaCell Therapeutics’ super NK cell technology is a significant milestone in cell therapy. With our extensive experience in 16 cell therapy IND approvals and our state-of-the-art facilities, Porton Advanced is well-suited to drive cell therapy industrialization across the world.”

About NovaCell Therapeutics

NovaCell Therapeutics was established in July 2025 in Hangzhou, China. Founded by a team of top scientists from Harvard, UCSF, WUSTL, the University of Pittsburgh, and other prestigious institutions, the company focuses on cancer immunotherapy and cell regenerative medicine.

About Porton Advanced

Porton Advanced Solutions is a subsidiary of the leading CDMO, Porton Pharma Solutions. Porton Advanced has headquarters in Cranbury, New Jersey, and two GMP sites in Suzhou, China, providing end-to-end CDMO solutions for ATMPs. We offer services from cell banking, process, and analytical method development, cGMP production to fill & finish, covering different stages of drug development from early research, IITs, Investigational New Drug (IND) applications, clinical trials, New Drug Applications (NDA), to commercialization.

Porton Advanced has developed specialized CRO and CDMO platforms focusing on plasmids, viral vectors (lentiviral vector, adenoviral vector, AAV,etc), cell therapy CMC services including CAR-T, TCR-T, CAR-NK, HSC, exosome, etc) and nucleic acid therapies. Our state-of-the-art, GMP-compliant facilities span an impressive 215,000 sqft, equipped with 10 viral vector production lines, 12 GMP-compliant cell therapy production suites (including 2 suites for infectious donors), and a multitude of clean rooms. As of now, we have successfully supported our clients to secure 20 global IND approvals from NMPA, FDA, and Medsafe, with 7 ongoing Phase I/II ATMP projects. Additionally, Porton Advanced has supported the successful transition of several overseas clinical-stage pipelines into China.

Porton Advanced is committed to a customer-centric approach, offering excellent global, end-to-end CDMO services to our clients, enabling effective drugs to benefit the public sooner.
For more information about Porton Advanced, please visit: www.portonadvanced.com.